- Synthetic Biology Faculty position
- SynBio2010 course in Synthetic Biology at Cambridge
- Synthetic Biology worth $4.5B by 2015
- Naked Scientist interview
- Royal Society: Future Technologies
- 2nd-generation GM traits
- NYT article about iGEM2009
- Synthetic Biology at the Wellcome Trust
- Giant Plant Cells
- Glass microbiology
- Endnote X3
- LEGO-sized hole punch
- Glowing Toyama Squid USB Memory Stick
- Green Pins
- Bacterial rainbow
- Synthetic operon for violacein production
- Cambridge team wins Grand Prize for iGEM2009
- The scatalog: E. chromi, pigment and poo
- Grand Prize for Cambridge iGEM2009 team
- Cambridge presentation at the iGEM2009 Jamboree
- Wellcome Trust iGEM2010 studentships
- Cambridge iGEM2009 team
- Synthetic Biology Project
- The iGEM Project
- RS Interface SynBio issue
- steam-powered dragon tin toy
- Magcloud: On Demand Magazine Printing
- RAE Synthetic Biology Report 2009
- Arduino Mega
- Phytocomp
- Computational Biology at Microsoft Research in Cambridge
- Open source hardware 2008
- www.synbio.org.uk news feeds
- Cambridge Network News
- iGEM 2008: Novice Bioengineers
- Plastic Logic e-Reader
- High Speed Photography using the Arduino
- Visitor's Guide to Cambridge
- Graduate Studies at Cambridge
- Emergence: a foundation for Synthetic Biology in Europe
- Bacillus Standards Working Group Meeting 1
- SynBioStandards UK Network in Synthetic Biology
- NumberKey turns your iPhone into a numeric Keypad
- Toast Bandages
- Soap Grenade
- Swiss Chocolate Knife
- Papercraft Turkey Dinner
- Miracle Fruit Tablets
- Wilting flower dies as your energy use blooms
- tikitag: RFID for the masses
- Predatory bacterial swarm uses rippling motion to reach prey
- Leonard et al Engineering microbes
- CatCam
- KAUST-Cambridge AEA
- iGEM2008 Jamboree
- Optical microscopy techniques for plants
- Computer modeling of plant morphogenesis
- Image Analysis of Cells
- Teaching materials from the University of Cambridge
- Scientific Computing in Cambridge
- Cheaposcope
- Gallery of Plant Images
- BioBrick vectors for Bacillus subtilis
- Tools for Arabidopsis
- Coleocheate as a model system
- Superfolder GFP
- IET Synthetic Biology
- Synthetic Biology in Plants
- Plant Visions exhibition
- iGEM2008 overview
- iGEM2009 studentships
- iGEM competition
- MIT Parts Registry
- An automated home-built low-cost fermenter suitable for large-scale bacterial expression of proteins in Escherichia coli.
- 90 billion tons of microbial organisms live in the deep biosphere
- Tesla 10 series
- The impact of online publishing
- The Moore's Law of microbiology - towards bacterial culture miniaturization with the micro-Petri chip.
- Moo does full-size business cards
- Handpresso - Portable Precise Espresso On the Go or at Home
- Book Darts
- Pinwheel and old VCR used to make wind-powered LED
- Firewinder LED windmill, for the eco-friendly barbershop
Amyris info
BLOG REPORT FROM GREENTECHMEDIA by ERIC WESOFF: APRIL 16, 2010 see http://www.greentechmedia.com/articles/read/amyris-files-to-go-public-biofuels-from-microbes/ In February, Michael Kanellos suggested that Amyris would be the next greentech startup to file to go public. It pains me greatly to write that he was correct. The synthetic biology firm, which has raisedmore than $244 million in private funding from Kleiner Perkins Caufield & Byers, Khosla Ventures, TPG Biotechnology, Advanced Equities, DAG Ventures, Grupo Cornélio Brennand, Naxos Capital Partners, The Westly Group, Stratus Group, and Temasek Holdings, et al. filed its SEC paperwork today and is looking to raise $100 million. Here's the link to the S-1. The company, which was spun out of research conducted at UC Berkeley, feeds sugars to custom microbes which exude hydrocarbons to order which are then converted to fuels or industrial chemicals. The CEO, John Melo, told Greentech Media in 2008 that $2 per gallon wholesale biodiesel was achievable. According to the S-1, Melo made $408,333 in salary, $200,000 in bonus, and $221,617 in other compensation for a total of $829,950 in 2009. The first product out of the company was an artificial version of artemisinin, an antimalaria drug that drew millions in support from the Bill and Melinda Gates Foundation. (Images from the S-1)Amyris Files to go Public—Biofuels from Microbes
The company has been busy. In December, it paid $82 million to Brazil's São Martinho Group for a 40-percent stake in an ethanol mill project that the parties hope will be operational by 2011 or 2012. The Brazilian company already controls three ethanol plants that make about 600 million liters (158 million gallons) of ethanol per year. Soon after, it entered into agreements with three other Brazilian companies -- Acucar Guarani, Bunge Limited and Cosan -- to produce ethanol and high-value chemicals.
Here are some tidbits from the SEC document:
Background
Risks
Amyris lists a confidence-sapping set of risks, standard for this type of document, which include:
Revenue
The company had 2007 sales of $6.1 million, 2008 sales of $13.9 million and 2009 sales of $64.6 million. The profits from those years were, just kidding -- the company lost $11.7 million, $41.8 million and a whopping $64.4 million in 2009.
Another biotech, company, Codexis, which makes enzymes for fuel production filed its S-1 in December. Vinod Khosla, an investor in Amyris, has voiced concern that "too many companies have filed and we will get a nanotech moment." He's "much more concerned about premature IPOs" and cites Codexis as "pretending to be a biofuels company when it is an R&D firm."
How is Amyris any different?